ArticleMalaria journal2025
Impact of seasonal malaria chemoprevention: a plausibility evaluation of routine data from health facilities in three implementing states in Nigeria.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeasonal malaria chemoprevention (SMC) has been recommended by the World Health Organization since 2012 for eligible children in areas where malaria transmission is highly seasonal and intense. By 2024, SMC had been successfully implemented in all 21 eligible states in Nigeria. Given this widespread implementation, there has been increasing interest in understanding the impact of the intervention under programmatic conditions. This study assessed changes in malaria case incidence and related epidemiological outcomes among the target population of children aged 3-59 months in three SMC implementing states in Nigeria.
methodsThe study employed a pre-post plausibility evaluation design. Data from routine health management information systems were extracted from selected health facilities to compare the incidence of parasitologically-confirmed uncomplicated malaria cases and secondary outcomes among children aged 3-59 months within the catchment populations of participating health facilities. Mixed-effects, multilevel, negative binomial regression models were used to estimate the impact of SMC on outcomes of interest between the pre-SMC period (2021) and SMC period (2022).
resultsData were collected in 36 health facilities: 12 each in Kogi state, Oyo state and the Federal Capital Territory. The mean incidence of uncomplicated malaria was 20 cases per 1000 children aged 3-59 months in 2021, and 9 cases per 1000 children in 2022. After accounting for potential confounders, malaria incidence was 50% (95% confidence interval [CI]: 39-60) lower in the SMC period compared with the pre-SMC period. The level of reduction varied across the three study locations, with the greatest impact in Oyo state and no evidence of impact in Kogi state. Incidence of all-cause fever per 1000 children was 29% (95% CI: 14-41) lower in 2022 compared with 2021. Observed levels of severe malaria and attributable deaths were too low to measure the impact of SMC on these secondary outcomes.
conclusionThe study found significantly lower levels of incidence of uncomplicated malaria cases following the introduction of SMC, although the magnitude of impact varied notably across locations. It thus provides evidence on the potential impact of the intervention under programmatic conditions, while underscoring the need to improve both the quality of SMC delivery to maximize impact, and the quality of routine data sources to enhance their utility for evaluating SMC impact in eligible settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.